AVCT Avacta Group Plc
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company's lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Avacta Group (LON: AVCT)
›
Avacta Group (LON: AVCT) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 81 employees.
The shares were at 60.50 GBp on 19 November 2026, down 16.0% over 52 weeks.
Its market capitalisation is 264.77M GBP.
Avacta Group reports flat revenue year over year.
It holds more cash than debt, a net cash position of 409.00K GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 90.50 GBp is 49.6% above the current price.